May 16, 2019

Anesthesia Considerations in HIPEC for Epithelial Ovarian Cancer

Careful management of adverse intraoperative events may reduce morbidity and mortality

DeBernardo_18-OBG-198_650x450

The use of hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreduction surgery (CRS) for epithelial ovarian cancer (EOC) can present metabolic and physiologic challenges that may alter the administration of intraoperative anesthesia, according to the findings of a new study presented at the 2019 Society for Gynecologic Oncology Annual Meeting in Honolulu, HI.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The retrospective review was directed by, Robert DeBernardo, MD, a gynecologic oncologist in the Department of Gynecologic Oncology and Director of Minimally Invasive Surgery in Cleveland Clinic’s Ob/Gyn & Women’s Health Institute. Dr. DeBernardo’s team retrospectively reviewed the cases of 64 women with diagnoses of EOC undergoing CRS with HIPEC between 2010 and 2018.

“We noticed some people develop acidosis when we started giving HIPEC, while others became hyperglycemic,” Dr. DeBernardo says. “There appeared to be a correlation with outcomes, which we sought to explore further.”

HIPEC comes with risks, but offers high rewards to select patients

HIPEC is a technique that delivers chemotherapy directly into the abdominal cavity, while the patient is still in the operating room, once resection is complete. Tubing is placed in the abdomen and chemotherapy—usually cisplatin—is circulated at 42° C.

“Once the cancer is removed, we infuse the abdomen with the drug for 90 minutes, reconnect the intestines if the bowel was involved in the surgery, and then close,” explains Dr. DeBernardo.

Advertisement

HIPEC perfusion: Following surgical removal of all gross cancer, tubing is placed in the abdomen and the patient is closed. An assistant at the bedside gently shakes the abdomen and the heated chemotherapy continually circulates for the prescribed time period.

HIPEC improves the rates of progression free survival and overall survival; however, the patient is kept under anesthesia for an additional 90 minutes, allowing us to expose the peritoneum to a very high concentrate of drug,” Dr. DeBernardo continues. “This added surgical stress can be hard on patients. We sometimes refer to this as a high-risk, high-reward procedure.”

Careful intraoperative management required

A vast majority of the patients experienced electrolyte abnormalities (96.9%) and required intraoperative pressor support (92.2%). Notably, 80.6% of patients developed hyperglycemia (>200 mg/dL) and 77.4% developed hypokalemia (3.5 mmol/L). Slightly less than half of the patients developed hypomagnesemia (<1.7mmol/L). Intraoperative insulin was administered in 60.9% of patients, and 60.8% received blood transfusions.

Of the 64 patients, 81.3% developed lactic acidosis intraoperatively, though there were no statistically significant differences between those with or without lactic acidosis in terms of outcomes, such as length of stay, postoperative adverse events, ICU admission, etc.).

Advertisement

“As we noticed a trend developing in the data, we became much more aggressive in our management of hyperglycemia and acidosis in the operating room. This, combined with the retrospective nature of this study, make it difficult to determine whether our own intraoperative interventions impacted the results.”

“When performing HIPEC procedures, care should be taken to monitor and maintain blood glucose, calcium and magnesium levels,” continues Dr. DeBernardo. “We put an arterial line in all of our patients so we can measure blood gas at any time during surgery, and we usually get results back within 5-10 minutes. We also noticed that glucose, particularly, as well as pH, are affected when we start the infusion. With acidosis, sometimes we adjust ventilator, or give bicarbonate. Careful management is key.”

Factors to consider in patient selection

Age, performance status and disease locations are all factors in selecting appropriate patients to receive HIPEC. “Not everyone is a great candidate for HIPEC,” Dr. DeBernardo explains. “If we can’t surgically remove all the cancer, then there will be no measurable benefit. A good candidate is one who is relatively healthy, and able to survive the treatment (i.e., not too frail) and move on to chemo afterward. We have also found HIPEC to move the survival curve dramatically for patients with platinum resistant ovarian cancer, for whom prognosis is usually quite poor. It’s a small group, but they fit in the high-risk, high-reward category: HIPEC may work for them when very little else does.”

Related Articles

Cleveland Clinic physiatrist
March 22, 2024
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

Ad